Pfizer Inc.
PFEHealthcareNASDAQDrug Manufacturers - General · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, Pfizer Inc. (PFE) is listed under Drug Manufacturers - General. The company carries a $162.16B market cap, placing it firmly in the large-cap category. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
Market Cap
$162.16B
Beta
0.30
P/E (TTM)
37.43
P/E (Fwd)
9.83
EPS (TTM)
$0.76
EPS (Fwd)
$2.90
ROE
5.0%
ROA
5.8%
Cash
$11.70B
Total Debt
$63.48B
Free CF
$12.49B
52W Change
15.1%
Annual Financials
Cash vs Debt
Where PFE stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PFE finished 12.48% above its 150-day moving average ($25.80) and 14.25% above its 200-day moving average ($25.40). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PFE overbought or oversold?
At the September 3, 2026 close, PFE's RSI(14) was 74.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, PFE has $11.70B in cash with $63.48B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $12.49B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 5.0% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $101.17B (2022) to $62.58B (2025), a 38% decline worth watching.
The relatively low beta of 0.30 suggests PFE is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Pfizer Inc.'s trajectory.